[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Power Life Sciences Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":478},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,77,0,25,[9,40,60,77,98,115,133,149,170,188,205,221,238,256,276,293,312,329,350,369,387,406,425,445,463],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100593747","exploring-acne-treatments-through-clinical-research-participation-100593747",false,"NCT07010458","Exploring Acne Treatments Through Clinical Research Participation","Advancing Acne Care - Clinical Trials Open for Patient Enrollment","Inclusion Criteria:\n\n* Patients diagnosed with acne.\n* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed\n* Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.\n\nExclusion Criteria:\n\n* Refusal of consent\n* Women of childbearing potential without a negative pregnancy test; or women who are lactating.\n* Any serious and\u002For unstable pre-existing medical disorders","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to understand the lived experiences of acne patients enrolled in a related clinical trial testing a particular treatment. The primary focus will be on tracking trial adherence and dropout rates to enhance future research and care approaches, especially for underserved groups.",[25],"Acne",[25],"NOT_YET_RECRUITING","2025-05-30",{"date":30,"type":31},"2025-06-08","ACTUAL",{"date":33,"type":21},"2026-06",{"date":35,"type":21},"2028-06",{"name":37,"class":38},"Power Life Sciences Inc.","INDUSTRY",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":39},"100542091","understanding-participation-habits-among-plaque-psoriasis-patients-100542091","NCT06338358","Understanding Participation Habits Among Plaque Psoriasis Patients","In the Patient's Words: Understanding Patient Participation and Engagement in Plaque Psoriasis Clinical Trials","Inclusion Criteria:\n\n* Patients diagnosed with plaque psoriasis\n* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed\n* Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.\n\nExclusion Criteria:\n\n* Refusal of consent\n* Women of childbearing potential without a negative pregnancy test; or women who are lactating.\n* Any serious and\u002For unstable pre-existing medical disorders",{"count":20,"type":21},"The study intends to investigate the personal experiences of plaque psoriasis patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal.\n\nThe data collected from this study will help improve future outcomes for all plaque psoriasis as well as those in under-represented demographic groups.",[50],"Plaque Psoriasis",[50],"2024-03-22",{"date":54,"type":31},"2024-03-29",{"date":56,"type":21},"2025-04",{"date":58,"type":21},"2027-04",{"name":37,"class":38},{"id":61,"slug":62,"hasResults":12,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":76,"locationsCount":39},"100542093","examining-engagement-trends-among-participants-in-peripheral-neuropathy-clinical-research-100542093","NCT06338384","Examining Engagement Trends Among Participants in Peripheral Neuropathy Clinical Research","A Study of Peripheral Neuropathy Clinical Trial Experiences: Insights From Patients","Inclusion Criteria:\n\n* Aged ≥ 18 years old\n* Diagnosis of peripheral neuropathy\n* Able to comprehend the investigational nature of the protocol and provide informed consent\n\nExclusion Criteria:\n\n* Female patients who are currently pregnant or nursing\n* Inability to perform regular electronic reporting\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial",{"count":20,"type":21},"This trial aims to uncover the factors driving patient decisions regarding enrollment, withdrawal, or re-engagement in peripheral neuropathy clinical trials. Understanding these factors will significantly improve the relevance and effectiveness of future research endeavors.\n\nUltimately, this trial endeavors to deepen our understanding of the factors impacting peripheral neuropathy clinical trial participation. Enhancing participation rates could accelerate the development of innovative treatments for this debilitating condition.",[70],"Peripheral Neuropathy",[72],"peripheral neuropathy",{"date":54,"type":31},{"date":56,"type":21},{"date":58,"type":21},{"name":37,"class":38},{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":39},"100536413","investigative-analysis-of-soft-tissue-sarcoma-clinical-trials-an-observational-study-100536413","NCT06264505","Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study","Probing Participation in Soft Tissue Sarcoma Research: An Observational Study of Soft Tissue Sarcoma Clinical Trials","Inclusion Criteria:\n\n* Patients diagnosed with soft tissue sarcoma\n* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed\n* Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.\n\nExclusion Criteria:\n\n* Refusal of consent\n* Women of childbearing potential without a negative pregnancy test; or women who are lactating.\n* Any serious and\u002For unstable pre-existing medical disorders",{"count":20,"type":21},"Generally, specific demographic cohorts exhibit higher participation rates in medical research, yet there exists a scarcity of research elucidating the trial attributes impacting the engagement of these particular demographics.\n\nThe primary objective of this study is to gather extensive data on the clinical trial experiences of individuals diagnosed with soft tissue sarcoma, with the aim of identifying factors hindering patient enrollment or trial completion.",[87],"Soft Tissue Sarcoma",[89],"soft tissue sarcoma","2024-02-23",{"date":92,"type":31},"2024-02-28",{"date":94,"type":21},"2025-03",{"date":96,"type":21},"2027-03",{"name":37,"class":38},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":113,"leadSponsor":114,"locationsCount":39},"100536412","delving-into-participation-trends-of-scleroderma-clinical-trials-100536412","NCT06264492","Delving Into Participation Trends of Scleroderma Clinical Trials","Deciphering Patient Participation: Insights From Observational Data in Scleroderma Clinical Trials","Inclusion Criteria:\n\n* Patient has been diagnosed with scleroderma\n* Patient has self-identified as planning to enroll in an observational clinical trial\n* Patient is a minimum of 18 years or older\n\nExclusion Criteria:\n\n* Patient is pregnant\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form",{"count":20,"type":21},"Typically, specific demographic subsets tend to exhibit greater engagement in medical research. Nonetheless, there is insufficient research elucidating the trial characteristics influencing the participation of these particular demographics.\n\nThe study will analyze data from diverse demographic viewpoints to uncover recurring trends that could provide valuable insights for future patients with scleroderma.",[108],"Scleroderma",[110],"scleroderma",{"date":92,"type":31},{"date":94,"type":21},{"date":96,"type":21},{"name":37,"class":38},{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":131,"leadSponsor":132,"locationsCount":39},"100538277","assessing-patient-engagement-in-keratoconus-clinical-research-100538277","NCT06288737","Assessing Patient Engagement in Keratoconus Clinical Research","Exploring Enrollment and Engagement Trends in Individuals Managing Keratoconus: A Comprehensive Examination of Data on Keratoconus Clinical Trials","Inclusion Criteria:\n\n* Signed Written Informed Consent\n* Aged ≥ 18 years old\n* No prior treatment for keratoconus\n\nExclusion Criteria:\n\n* Participant is actively receiving study therapy in another\n* Inability to provide written informed consent\n* Women of childbearing potential without a negative pregnancy test; or women who are lactating.",{"count":20,"type":21},"This study aims to investigate the influences behind patient choices regarding involvement, discontinuation, or re-engagement in keratoconus clinical trials. Uncovering these factors is essential to enhance the relevance and efficacy of future research endeavors.\n\nIn essence, this trial aims to deepen understanding of the factors influencing participation in keratoconus clinical trials. Elevating participation rates could expedite the development of innovative treatments for this challenging condition.",[125],"Keratoconus",[127],"keratoconus",{"date":129,"type":31},"2024-03-01",{"date":94,"type":21},{"date":96,"type":21},{"name":37,"class":38},{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":148,"locationsCount":39},"100538274","understanding-patient-engagement-trends-in-tbi-clinical-research-100538274","NCT06288698","Understanding Patient Engagement Trends in TBI Clinical Research","Analyzing Enrolment and Engagement Trends in Individuals Confronting TBI: Insights From TBI Clinical Trials","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document\n* Participant must be 18 years of age or older\n* Confirmed diagnosis of TBI\n\nExclusion Criteria:\n\n* Enrolled in another research study\n* Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study\n* Inability to provide written informed consent",{"count":20,"type":21},"Clinical trials, specifically focused on TBI, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation.\n\nThe main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.",[143],"TBI",[143],{"date":129,"type":31},{"date":94,"type":21},{"date":96,"type":21},{"name":37,"class":38},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100491135","exploring-clinical-trial-experiences-of-patients-with-migraine-100491135","NCT05675189","Exploring Clinical Trial Experiences of Patients With Migraine","An In Depth Study Examining Patterns in the Clinical Trial Experiences of Migraine Patients","Inclusion Criteria:\n\n* Patient is a minimum of 18 years of age\n* Patient has been diagnosed with a type of migraine\n* Patient plans to participate in an interventional clinical trial for the condition of migraine\n* Patient has access to a home internet connection in order to provide regular updates through the course of the study\n\nExclusion Criteria:\n\n* Patient has an ECOG score of 4 or higher\n* Patient is not able to provide consistent digital updates as per study requirements\n* Patient does not complete or agree to terms outlined in the Informed Consent Form","65 Years",{"count":20,"type":21},"Clinical study participation has historically been heavily biased toward specific demographics.\n\nThis study will invite several participants to gather a wide range of information on clinical trial experiences for migraine patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of migraine.\n\nPeople with migraine who are invited to take part in medical research will benefit from the analysis of the data.",[160,161],"Migraine","Migraine Disorders",[160],{"date":164,"type":31},"2024-02-26",{"date":166,"type":21},"2025-01",{"date":168,"type":21},"2027-01",{"name":37,"class":38},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":186,"leadSponsor":187,"locationsCount":39},"100536414","an-observational-exploration-of-clinical-trials-targeting-traumatic-brain-injury-100536414","NCT06264518","An Observational Exploration of Clinical Trials Targeting Traumatic Brain Injury","Exploration of Traumatic Brain Injury Clinical Trials: Unveiling Patient Participation Patterns","Inclusion Criteria:\n\n* Patient has been diagnosed with traumatic brain injury\n* Patient has self-identified as planning to enroll in an observational clinical trial\n* Patient is a minimum of 18 years or older\n\nExclusion Criteria:\n\n* Pregnant or nursing patients\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form",{"count":20,"type":21},"Clinical study participation has historically been heavily biased toward specific demographics.\n\nSeveral people will be invited to enroll in this study so that it may collect a variety of data about traumatic brain injury clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.\n\nPeople with traumatic brain injury who are invited to take part in medical research will benefit from the analysis of the data.",[180],"Traumatic Brain Injury",[180],"2024-02-09",{"date":184,"type":31},"2024-02-20",{"date":94,"type":21},{"date":96,"type":21},{"name":37,"class":38},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":203,"leadSponsor":204,"locationsCount":39},"100531606","revealing-engagement-patterns-among-hepatic-encephalopathy-patients-100531606","NCT06201988","Revealing Engagement Patterns Among Hepatic Encephalopathy Patients","Assessing Patient Engagement and Understanding in Hepatic Encephalopathy Clinical Research","Inclusion Criteria:\n\n* Signed Written Informed Consent\n* Aged ≥ 18 years old\n* No prior treatment for hepatic encephalopathy\n\nExclusion Criteria:\n\n* Participant is actively receiving study therapy in another\n* Inability to provide written informed consent\n* Women of childbearing potential without a negative pregnancy test; or women who are lactating.",{"count":20,"type":21},"This study aims to investigate the influences behind patient choices regarding involvement, discontinuation, or re-engagement in hepatic encephalopathy clinical trials. Uncovering these factors is essential to enhance the relevance and efficacy of future research endeavors.\n\nIn essence, this trial aims to deepen understanding of the factors influencing participation in hepatic encephalopathy clinical trials. Elevating participation rates could expedite the development of innovative treatments for this challenging condition.",[198],"Hepatic Encephalopathy",[198],{"date":201,"type":31},"2024-02-12",{"date":166,"type":21},{"date":168,"type":21},{"name":37,"class":38},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":219,"leadSponsor":220,"locationsCount":39},"100531596","a-journey-into-participation-patterns-among-patients-with-hidradenitis-suppurativa-100531596","NCT06201858","A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurativa","Examining Engagement Trends Among Participants in Hidradenitis Suppurativa Clinical Trials","Inclusion Criteria:\n\n* Aged ≥ 18 years old\n* Diagnosis of hidradenitis suppurativa\n* Able to comprehend the investigational nature of the protocol and provide informed consent\n\nExclusion Criteria:\n\n* Female patients who are currently pregnant or nursing\n* Inability to perform regular electronic reporting\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",{"count":20,"type":21},"This study aims to uncover the factors driving patient decisions regarding enrollment, withdrawal, or re-engagement in hidradenitis suppurativa clinical trials. Understanding these factors will significantly improve the relevance and effectiveness of future research endeavors.\n\nUltimately, this trial endeavors to deepen our understanding of the factors impacting hidradenitis suppurativa clinical trial participation. Enhancing participation rates could accelerate the development of innovative treatments for this debilitating condition.",[215],"Hidradenitis Suppurativa",[215],{"date":201,"type":31},{"date":166,"type":21},{"date":168,"type":21},{"name":37,"class":38},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":236,"leadSponsor":237,"locationsCount":39},"100529493","investigating-participation-patterns-of-patients-in-atopic-dermatitis-clinical-trials-100529493","NCT06174493","Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials","Understanding Patient Engagement Trends in Atopic Dermatitis Clinical Research","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document\n* Participant must be 18 years of age or older\n* Confirmed diagnosis of atopic dermatitis\n\nExclusion Criteria:\n\n* Enrolled in another research study\n* Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study\n* Inability to provide written informed consent",{"count":20,"type":21},"Clinical trials, specifically focused on atopic dermatitis, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation.\n\nThe main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.",[231],"Atopic Dermatitis",[233],"atopic dermatitis",{"date":201,"type":31},{"date":166,"type":21},{"date":168,"type":21},{"name":37,"class":38},{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":254,"leadSponsor":255,"locationsCount":39},"100535617","understanding-of-participation-trends-within-generalized-anxiety-disorder-patients-involved-in-clinical-trials-100535617","NCT06254157","Understanding of Participation Trends Within Generalized Anxiety Disorder Patients Involved in Clinical Trials","Generalized Anxiety Disorder Clinical Trials: An Analysis Regarding Engagement Trends and Participation of Generalized Anxiety Disorder Patients Involved in Clinical Trials","Inclusion Criteria:\n\n* Confirmed diagnosis of generalized anxiety disorder\n* Participant must be 18 years of age or older\n* Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.\n\nExclusion Criteria:\n\n* Pregnant or lactating woman\n* Participant is actively receiving study therapy in another\n* Inability to provide written informed consent",{"count":20,"type":21},"Typically, certain demographic groups tend to participate more in medical research. However, there is insufficient research explaining the trial characteristics that influence the involvement of these specific demographics.\n\nThis study aims to collect extensive data on the clinical trial experiences of individuals with generalized anxiety disorder. The goal is to identify the factors that hinder a patient's enrollment or completion of a trial.\n\nAdditionally, the research will examine the data from various demographic perspectives to identify recurring patterns that could offer valuable insights for future generalized anxiety disorder patients.",[248],"Generalized Anxiety Disorder",[250],"generalized anxiety disorder","2024-02-02",{"date":201,"type":31},{"date":94,"type":21},{"date":96,"type":21},{"name":37,"class":38},{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":39},"100532893","revealing-engagement-dynamics-among-semantic-dementia-patients-100532893","NCT06218732","Revealing Engagement Dynamics Among Semantic Dementia Patients","Understanding Participation Habits: An Observational Investigation Within Semantic Dementia Clinical Trials","Inclusion Criteria:\n\n* Patients diagnosed with semantic dementia\n* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed\n* Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.\n\nExclusion Criteria:\n\n* Refusal of consent\n* Women of childbearing potential without a negative pregnancy test; or women who are lactating.\n* Any serious and\u002For unstable pre-existing medical disorders",{"count":20,"type":21},"The study intends to investigate the personal experiences of semantic dementia patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal.\n\nThe data collected from this study will help improve future outcomes for all semantic dementia as well as those in under-represented demographic groups.",[266],"Semantic Dementia",[266],"2024-01-12",{"date":270,"type":31},"2024-01-23",{"date":272,"type":21},"2025-02",{"date":274,"type":21},"2027-02",{"name":37,"class":38},{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":284,"conditions":285,"keywords":287,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":292,"locationsCount":39},"100532892","studying-patterns-in-patient-engagement-among-tardive-dyskinesia-patients-100532892","NCT06218719","Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients","Examining Engagement Patterns: An Observational Exploration About Tardive Dyskinesia Clinical Trials","Inclusion Criteria:\n\n* Diagnosis of tardive dyskinesia\n* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed\n* No prior treatment for tardive dyskinesia\n\nExclusion Criteria:\n\n* Enrolled in another research study\n* Inability to provide written informed consent\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial",{"count":20,"type":21},"The statistical analysis of the collected data aims to reveal the many factors that influence patient involvement in clinical trials. Findings will be disseminated through conferences and scholarly papers to benefit all parties participating in clinical trials.\n\nThese findings will help to shape the design of future clinical trials for people with tardive dyskinesia, as well as enhance recruiting techniques and retention rates.",[286],"Tardive Dyskinesia",[288],"tardive dyskinesia",{"date":270,"type":31},{"date":272,"type":21},{"date":274,"type":21},{"name":37,"class":38},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":301,"conditions":302,"keywords":304,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":310,"leadSponsor":311,"locationsCount":39},"100532060","exploring-clinical-study-experiences-of-people-with-anorexia-nervosa-100532060","NCT06207890","Exploring Clinical Study Experiences of People With Anorexia Nervosa","An Analysis of Participation Trends: Observing Patient Engagement in Anorexia Nervosa Clinical Trials","Inclusion Criteria:\n\n* Patient has self-identified as planning to enroll in a clinical trial\n* Patient has been diagnosed with anorexia nervosa\n* Patient is a minimum of 18 years or older\n\nExclusion Criteria:\n\n* Patient does not understand, sign, and return consent form\n* Inability to perform regular electronic reporting\n* Patient is pregnant",{"count":20,"type":21},"The study seeks to delve into the firsthand experiences of patients diagnosed with anorexia nervosa who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.\n\nBy joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future anorexia nervosa patients and play an active role in advancing medical research.",[303],"Anorexia Nervosa",[305],"anorexia nervosa","2024-01-05",{"date":308,"type":31},"2024-01-17",{"date":272,"type":21},{"date":274,"type":21},{"name":37,"class":38},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":327,"leadSponsor":328,"locationsCount":39},"100532061","navigating-the-clinical-research-process-for-mild-cognitive-impairment-100532061","NCT06207903","Navigating the Clinical Research Process for Mild Cognitive Impairment","Investigating Participation Behavior: An Observational Study in Mild Cognitive Impairment Clinical Trials","Inclusion Criteria:\n\n* Confirmed diagnosis of mild cognitive impairment\n* Participant must be 18 years of age or older\n* Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.\n\nExclusion Criteria:\n\n* Pregnant or lactating woman\n* Participant is actively receiving study therapy in another\n* Inability to provide written informed consent",{"count":20,"type":21},"Participation in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.\n\nThis trial will admit a wide range of data on the clinical trial experience of mild cognitive impairment patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.\n\nIt will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future mild cognitive impairment patients.",[322],"Mild Cognitive Impairment",[324],"mild cognitive impairment",{"date":308,"type":31},{"date":272,"type":21},{"date":274,"type":21},{"name":37,"class":38},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":4},"100477942","finding-patterns-in-clinical-study-experiences-of-multiple-sclerosis-patients-100477942","NCT05503524","Finding Patterns In Clinical Study Experiences of Multiple Sclerosis Patients","Extensive Clinical Trial Experiences of Multiple Sclerosis Patients To Determine Trial Attributes Affecting Completion Rates For Specific Demographic Groups","Inclusion Criteria:\n\n* Participant has a diagnosis of Multiple Sclerosis\n* Patient has self-identified as planning to enroll in an interventional clinical trial for Multiple Sclerosis\n* Patient is at least 18 years of age\n\nExclusion Criteria:\n\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form\n* No diagnosis of Multiple Sclerosis confirmed",{"count":20,"type":21},"Participation in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.\n\nThis study will admit a wide range of data on the clinical trial experience of Multiple Sclerosis patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.\n\nIt will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future Multiple Sclerosis patients.",[339],"Multiple Sclerosis",[339,341],"Sclerosis","2023-12-29",{"date":344,"type":31},"2024-01-02",{"date":346,"type":21},"2024-09",{"date":348,"type":21},"2026-09",{"name":37,"class":38},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":4},"100480384","assessing-clinical-trial-experiences-of-patients-with-osteosarcoma-100480384","NCT05535283","Assessing Clinical Trial Experiences of Patients With Osteosarcoma","An Observational Study Investigating The Experiences of Patients In Osteosarcoma Clinical Trials","Inclusion Criteria:\n\n* Patient has been diagnosed with osteosarcoma\n* Patient has self-identified as planning to enroll in an interventional clinical trial\n* Patient is a minimum of 18 years or older\n\nExclusion Criteria:\n\n* ECOG score of 4\n* Patient is pregnant\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form",{"count":20,"type":21},"Clinical study participation has historically been heavily biased toward specific demographics.\n\nSeveral people will be invited to enroll in this study so that it may collect a variety of data about osteosarcoma clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.\n\nPeople with osteosarcoma who are invited to take part in medical research will benefit from the analysis of the data.",[360],"Osteosarcoma",[362],"osteosarcoma",{"date":344,"type":31},{"date":365,"type":21},"2024-10",{"date":367,"type":21},"2026-10",{"name":37,"class":38},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":385,"leadSponsor":386,"locationsCount":4},"100478923","evaluating-clinical-trial-experiences-of-individuals-with-congestive-heart-failure-100478923","NCT05516290","Evaluating Clinical Trial Experiences of Individuals With Congestive Heart Failure","An In Depth Study Investigating Patterns of Patients In Congestive Heart Failure Clinical Trials","Inclusion Criteria:\n\n* Lives in the United States\n* Is 18+ years old\n* Participant has a diagnosis of congestive heart failure\n* Participant has enrolled in an interventional clinical for congestive heart failure (self-reported)\n\nExclusion Criteria:\n\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form\n* No diagnosis of congestive heart failure confirmed",{"count":20,"type":21},"Clinical trial participation has always been substantially skewed toward certain demographic groups. However, there has been little study on whether trial qualities impact participation in either a positive or negative way. The goal of this research is to identify the characteristics that consistently restrict patients' ability to participate in or complete a trial in which they were initially interested. This data will be evaluated via a number of demographic lenses in order to find trends that could benefit future Congestive Heart Failure sufferers.",[379],"Congestive Heart Failure",[381,382],"congestive heart failure","heart failure",{"date":344,"type":31},{"date":346,"type":21},{"date":348,"type":21},{"name":37,"class":38},{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":4},"100476418","analyzing-orthopedic-patient-experience-patterns-in-medical-trials-100476418","NCT05483673","Analyzing Orthopedic Patient Experience Patterns in Medical Trials","A Comprehensive Study for Analyzing Orthopedic Patient Experience Patterns in Medical Trials","Inclusion Criteria:\n\n* Patient has been diagnosed with orthopedic disorder\n* Patient has self-identified as planning to enroll in an interventional clinical trial\n* Patient is 18 years old\n\nExclusion Criteria:\n\n* ECOG score of 4\n* Patient is pregnant\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form",{"count":20,"type":21},"Clinical study enrollment has historically been heavily biased toward specific demographics.\n\nSeveral people will be invited to participate in this study so that it may collect a variety of data about orthopedic clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.\n\nPeople with orthopedic disorders who are invited to take part in medical research will benefit from the analysis of the data.",[397],"Orthopedic Disorder",[399],"orthopedic",{"date":344,"type":31},{"date":402,"type":21},"2024-08",{"date":404,"type":21},"2026-08",{"name":37,"class":38},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":414,"conditions":415,"keywords":418,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":423,"leadSponsor":424,"locationsCount":4},"100474697","determining-patterns-in-trial-experiences-of-diabetic-neuropathy-patients-100474697","NCT05461274","Determining Patterns In Trial Experiences of Diabetic Neuropathy Patients","An In Depth Study Examining Patterns in the Clinical Trial Experiences of Diabetic Neuropathy Patients","Inclusion Criteria:\n\n* Patient plans to participate in an interventional clinical trial for the condition of diabetic neuropathy\n* Patient has been diagnosed with a type of diabetic neuropathy\n* Patient is a minimum of 18 years of age\n* Patient has access to a home internet connection in order to provide regular updates through the course of the study\n\nExclusion Criteria:\n\n* Patient is not able to provide consistent digital updates as per study requirements\n* Patient does not complete or agree to terms outlined in the Informed Consent Form\n* Patient has an ECOG score of 4 or higher",{"count":20,"type":21},"Historically, participation in clinical studies is highly skewed towards particular demographic groups of people.\n\nThis study will invite several participants to gather a wide range of information on clinical trial experiences for diabetic neuropathy patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of diabetic neuropathy.\n\nThe data collected from this study will help improve future outcomes for all diabetic neuropathy patients as well as those in under-represented demographic groups.",[416,417],"Diabetic Neuropathies","Diabetic Neuropathy Peripheral",[419,420],"diabetic neuropathy","neuropathy",{"date":344,"type":31},{"date":402,"type":21},{"date":404,"type":21},{"name":37,"class":38},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":432,"minAge":18,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":443,"leadSponsor":444,"locationsCount":39},"100470860","analyzing-clinical-trial-experiences-of-prostate-cancer-patients-100470860","NCT05411354","Analyzing Clinical Trial Experiences of Prostate Cancer Patients","Analyzing Clinical Trial Experiences of Prostate Cancer Patients To Determine How Trial Attributes Affect Completion Rates For Specific Demographic Groups","Inclusion Criteria:\n\n* Patient has been diagnosed with Prostate Cancer as identified by imaging\n* Patient has self-identified as planning to enroll in an interventional clinical trial for Prostate Cancer\n* Patient is at least 18 years of age\n\nExclusion Criteria:\n\n* Patient does not understand, sign, and return consent form\n* Inability to perform regular electronic reporting\n* Patient has a ECOG score of 4","MALE",{"count":434,"type":21},400,"Participation in clinical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the participation or completion of these specific demographic groups.\n\nThis study will admit a wide range of data on the clinical trial experience of Prostate Cancer patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.\n\nIt will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might shed insights for the sake of future Prostate Cancer patients.",[437],"Prostate Cancer",[437,439,440],"Prostate","Prostate Clinical Trials",{"date":344,"type":31},{"date":346,"type":21},{"date":348,"type":21},{"name":37,"class":38},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":453,"conditions":454,"keywords":457,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":461,"leadSponsor":462,"locationsCount":4},"100472706","investigating-the-experiences-of-patients-in-immunotherapy-clinical-trials-100472706","NCT05435365","Investigating The Experiences of Patients In Immunotherapy Clinical Trials","An Observational Study Investigating The Experiences of Patients In Immunotherapy Clinical Trials","Inclusion Criteria:\n\n* Patient has self-identified as planning to participate in an interventional clinical trial using immunotherapy\n* Patient has been diagnosed with a type of cancer\n* Patient is a minimum of 18 years or older\n\nExclusion Criteria:\n\n* Patient has an ECOG score of 4 or higher\n* Patient is not able to provide consistent digital reporting as per study requirements\n* Patient does not complete Informed Consent Form",{"count":20,"type":21},"It has been observed before that participation in medical trials has been in favor of specific demographic groups. But research pointing out which trial attributes impact participation positively or negatively is sparse.\n\nThis study invites various participants to collect more data on their immunotherapy clinical experiences. The goal is to know which factors always limit how patients participate or complete the medical study they are first interested in.\n\nThe data obtained in the trial will be assessed through a variety of demographic lenses to discover patterns that might improve the experience of immunotherapy patients in the future.",[455,456],"Immunotherapy","Cancer",[455,456,458],"Diversity In Immunotherapy Clinical Trials",{"date":344,"type":31},{"date":402,"type":21},{"date":404,"type":21},{"name":37,"class":38},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":476,"leadSponsor":477,"locationsCount":39},"100469873","medical-trial-appraising-medical-trial-experiences-of-rheumatoid-arthritis-patients-100469873","NCT05398471","Medical Trial: Appraising Medical Trial Experiences of Rheumatoid Arthritis Patients","Observational Clinical Trial Appraising Medical Trial Experiences of Rheumatoid Arthritis Patients Participating In Clinical Research","Inclusion Criteria:\n\n* Patient has been diagnosed with rheumatoid arthritis\n* Patient has self-identified as planning to enroll in an interventional clinical trial\n* Patient is 18 years old\n\nExclusion Criteria:\n\n* ECOG score of 4\n* Patient is pregnant\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form",{"count":20,"type":21},"Historically, participation in clinical trials has been highly skewed towards specific demographic groups. However, research identifying which trial attributes impact participation, in either positive or negative ways, is limited. This study invites participants to record a wide range of data on their clinical trial experience, with the goal being to identify factors which persistently limit patients' ability to participate in, or complete, a trial in which they were initially interested. This data will be analyzed through a range of demographic lenses, in hopes of discovering patterns which might improve the experience of future rheumatoid arthritis patients.",[473],"Rheumatoid Arthritis",{"date":344,"type":31},{"date":402,"type":21},{"date":404,"type":21},{"name":37,"class":38},""]